IOL Chemicals and Pharmaceuticals Limited

rs,

Complex, Bandra (E) Mumbai - 400 051 Security Symbol: IOLCP BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street Mumbai- 400 001 Security Code: 524164 Subject: Investor Presentation-Q4 FY2025. D

10,800 MT

• • • Commissioned Unit-11 for Paracetamol production at Barnala with an installed capacity of 10,800 MTPA on 24th March 2025 The ₹155.51 crore investment, fully funded through internal accruals, enhances

₹155.51 crore

Paracetamol production at Barnala with an installed capacity of 10,800 MTPA on 24th March 2025 The ₹155.51 crore investment, fully funded through internal accruals, enhances backward integration and scale. Clop

180 MT

ces backward integration and scale. Clopidogrel Bisulphate production capacity was increased from 180 MTPA to 240 MTPA at Unit-5. The ₹7.87 crore expansion was successfully completed on 24th March 2025,

240 MT

integration and scale. Clopidogrel Bisulphate production capacity was increased from 180 MTPA to 240 MTPA at Unit-5. The ₹7.87 crore expansion was successfully completed on 24th March 2025, funded entir

₹7.87 crore

Clopidogrel Bisulphate production capacity was increased from 180 MTPA to 240 MTPA at Unit-5. The ₹7.87 crore expansion was successfully completed on 24th March 2025, funded entirely through internal resource

₹ 527.8

for exporting Ibuprofen to the Chinese market. 3 Q4 & FY25 Performance Highlights Q4FY25 FY25 ₹ 527.8 Cr Revenue from Operations ₹ 2079.2 Cr Revenue from Operations ₹ 67.5 Cr EBITDA Margin 12.7% ₹ 22

₹ 2079.2

ese market. 3 Q4 & FY25 Performance Highlights Q4FY25 FY25 ₹ 527.8 Cr Revenue from Operations ₹ 2079.2 Cr Revenue from Operations ₹ 67.5 Cr EBITDA Margin 12.7% ₹ 224.6 Cr EBITDA Margin 10.7% ₹ 31.6 Cr

₹ 67.5

Highlights Q4FY25 FY25 ₹ 527.8 Cr Revenue from Operations ₹ 2079.2 Cr Revenue from Operations ₹ 67.5 Cr EBITDA Margin 12.7% ₹ 224.6 Cr EBITDA Margin 10.7% ₹ 31.6 Cr Profit After Tax Margin 5.9% ₹ 10

12.7%

5 ₹ 527.8 Cr Revenue from Operations ₹ 2079.2 Cr Revenue from Operations ₹ 67.5 Cr EBITDA Margin 12.7% ₹ 224.6 Cr EBITDA Margin 10.7% ₹ 31.6 Cr Profit After Tax Margin 5.9% ₹ 101.0 Cr Profit After Ta

₹ 224.6

7.8 Cr Revenue from Operations ₹ 2079.2 Cr Revenue from Operations ₹ 67.5 Cr EBITDA Margin 12.7% ₹ 224.6 Cr EBITDA Margin 10.7% ₹ 31.6 Cr Profit After Tax Margin 5.9% ₹ 101.0 Cr Profit After Tax Margin 4

10.7%

tions ₹ 2079.2 Cr Revenue from Operations ₹ 67.5 Cr EBITDA Margin 12.7% ₹ 224.6 Cr EBITDA Margin 10.7% ₹ 31.6 Cr Profit After Tax Margin 5.9% ₹ 101.0 Cr Profit After Tax Margin 4.8% Pharmaceuticals

“Asia-Pacific—led by India and China posts the fastest growth at 8.7% CAGR.”

“Aiming to grow export revenue share to ~40% The company has acquired 101 acres of land alongside the Chandigarh- Bathinda Highway, near its existing facility, to support future expansion.”

Existing Facility

1

COMPANY

1

INVESTOR RELATIONS ADVISORS

1

Existing Facility

Spanning 180+ acres Expansion: Acquired 101 acres on Chandigarh- Bathinda Highway for new site development Zero Discharge Effluent Treatment Plant Largest producer of Ibuprofen and the only company worldwide being backward integrated with ~30% Global share Customer base across 80 countries DSIR-approved R&D facility with 50+ scientists driving innovation across APIs and specialty chemicals Over 20 products are commercialized with 8 products in pipeline Major producer of Ethyl Acetate in India, producing 1,00,000 MTPA Net Debt to Equity Ratio 0.09 10 Segment Overview- Pharmaceuticals Largest global producer of Ibuprofen, with a ~30% market share and over 12,000 MT capacity World’s only company with full backward integration for all Ibuprofen intermediates and KSMs Filed 16 DMFs with USFDA and 19 CEPs with EDQM CEP certification received for 16 APIs, enabling exports to Europe and other CEP-accepting countries Commenced a fully backward-integrated Unit-11 for Paracetamol manufacturing at

COMPANY

IOL Chemicals and Pharmaceuticals Ltd. CIN : L24116PB1986PLC007030 Mr. Abhay Raj Singh - Sr. VP & Company Secretary E-mail: investor@iolcp.com www.iolcp.com investor@iolcp.com www.iolcp.com Thank You

INVESTOR RELATIONS ADVISORS

MUFG Intime India Private Limited A part of MUFG Corporate Markets, a division of MUFG Pension & Market Services Ms. Prachi Ambre +91 83559 85370 Prachi.ambre@in.mpms.mufg.com Ms. Irfan Raeen +91 97737 78669 irfan.raeen@in.mpms.mufg.com